id
stringlengths 7
11
| context
stringlengths 24
527
| is_mult_event
bool 2
classes | annotations
list |
|---|---|---|---|
18801826_1 | Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[11]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Olanzapine\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Olanzapine\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"hyperglycaemic coma and neuroleptic malignant syndrome\"]], \"start\": [[19]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
15494638_20 | Neurologic symptoms resolved after stopping CAP for 4 weeks in Patient A, with no recurrence after reinitiating CAP alone at 2000 mg/m2. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[29]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Neurologic symptoms resolved\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"stopping CAP for 4 weeks\"]], \"start\": [[35]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"CAP\"]], \"start\": [[44]], \"entity_id\": [\"T7\"]}, \"Time_elapsed\": {\"text\": [[\"4 weeks\"]], \"start\": [[52]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
17381671_11 | OBJECTIVE: To report a case of serotonin syndrome associated with interaction between fentanyl and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[66]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[21]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"serotonin syndrome\"]], \"start\": [[31]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"fentanyl and citalopram\"]], \"start\": [[86]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"fentanyl\"], [\"citalopram\"]], \"start\": [[86], [99]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[95]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"fentanyl\"], [\"citalopram\"]], \"start\": [[86], [99]], \"entity_id\": [\"T9\", \"T10\"]}}]}}"
}
]
}
] |
17968817_2 | We report (to our knowledge, for the first time in a child) the emergence of psychosis in a 12-year old white girl with an increased efavirenz concentration and heterozygous gene polymorphism of the CYP2B6-G516T. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"emergence\"]], \"start\": [[64]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"psychosis\"]], \"start\": [[77]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"a 12-year old white girl\", \"heterozygous gene polymorphism of the CYP2B6-G516T\"]], \"start\": [[90, 161]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"12-year old\"]], \"start\": [[92]], \"entity_id\": [\"T7\"]}, \"Race\": {\"text\": [[\"white\"]], \"start\": [[104]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"girl\"]], \"start\": [[110]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"increased efavirenz concentration\"]], \"start\": [[123]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"efavirenz\"]], \"start\": [[133]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
12114387_2 | Severe erythroderma as a complication of continuous epoprostenol therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[25]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Severe erythroderma\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"continuous epoprostenol\"]], \"start\": [[41]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"epoprostenol\"]], \"start\": [[52]], \"entity_id\": [\"T7\"]}, \"Freq\": {\"text\": [[\"continuous\"]], \"start\": [[41]], \"entity_id\": [\"T8\"]}}, \"Severity\": {\"text\": [[\"Severe\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"value\": \"Medium\"}}"
}
]
}
] |
18717612_2 | FDE from cephalosporins has been rarely reported, and to the best of our knowledge there is no published report of ceftriaxone-induced FDE in the literature. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"from\"]], \"start\": [[4]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"FDE\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"cephalosporins\"]], \"start\": [[9]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"cephalosporins\"]], \"start\": [[9]], \"entity_id\": [\"T8\"]}}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[127]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"ceftriaxone\"]], \"start\": [[115]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"ceftriaxone\"]], \"start\": [[115]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"FDE\"]], \"start\": [[135]], \"entity_id\": [\"T11\"]}}"
}
]
}
] |
12503933_3 | CASE SUMMARY: A 58-year-old white woman developed fulminant liver failure while being treated with the macrolide antibiotic clarithromycin for pneumonia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[40]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"A 58-year-old white woman\"]], \"start\": [[14]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"58-year-old\"]], \"start\": [[16]], \"entity_id\": [\"T8\"]}, \"Race\": {\"text\": [[\"white\"]], \"start\": [[28]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[34]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"fulminant liver failure\"]], \"start\": [[50]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"macrolide antibiotic clarithromycin for pneumonia\"]], \"start\": [[103]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"pneumonia\"]], \"start\": [[143]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"clarithromycin\"]], \"start\": [[124]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
10410183_10 | CONCLUSIONS: Marked elevation of serum CK may be a possible complication of olanzapine therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[60]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Marked elevation of serum CK\"]], \"start\": [[13]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"olanzapine therapy\"]], \"start\": [[76]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"olanzapine\"]], \"start\": [[76]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
12163813_2 | OBJECTIVE: To describe a case of severe skin necrosis resulting from peripheral intravenous administration of low-dose vasopressin in a patient with catecholamine-resistant septic shock. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"resulting\"]], \"start\": [[54]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"a patient with catecholamine-resistant septic shock\"]], \"start\": [[134]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"skin necrosis\"]], \"start\": [[40]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"peripheral intravenous administration of low-dose vasopressin\"]], \"start\": [[69]], \"entity_id\": [\"T6\"], \"Route\": {\"text\": [[\"peripheral intravenous administration\"]], \"start\": [[69]], \"entity_id\": [\"T9\"]}, \"Dosage\": {\"text\": [[\"low-dose\"]], \"start\": [[110]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"vasopressin\"]], \"start\": [[119]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"catecholamine-resistant septic shock\"]], \"start\": [[149]], \"entity_id\": [\"T12\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[33]], \"entity_id\": [\"T8\"], \"value\": \"High\"}}"
}
]
}
] |
8445549_1 | Although the essential cause of PV is unclear, its onset has occasionally been associated with drug therapy, in particular penicillamine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[79]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"penicillamine\"]], \"start\": [[123]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"penicillamine\"]], \"start\": [[123]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"PV\"]], \"start\": [[32]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
8031432_1 | Recurrent hypotension immediately after seizures in nortriptyline overdose. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[49]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Recurrent hypotension immediately after seizures\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"nortriptyline overdose\"]], \"start\": [[52]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"nortriptyline\"]], \"start\": [[52]], \"entity_id\": [\"T8\"]}, \"Dosage\": {\"text\": [[\"overdose\"]], \"start\": [[66]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
12460237_4 | We report a patient with recurrent, increasingly severe episodes of PPE, ultimately complicated by a severe bullous eruption, following successive cycles of high-dose cytarabine for the treatment of acute lymphoblastic leukaemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[126]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[10]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"recurrent, increasingly severe episodes of PPE, ultimately complicated by a severe bullous eruption\"]], \"start\": [[25]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"cycles of high-dose cytarabine for the treatment of acute lymphoblastic leukaemia\"]], \"start\": [[147]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"acute lymphoblastic leukaemia\"]], \"start\": [[199]], \"entity_id\": [\"T11\"]}, \"Dosage\": {\"text\": [[\"high-dose\"]], \"start\": [[157]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"cytarabine\"]], \"start\": [[167]], \"entity_id\": [\"T15\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[101]], \"entity_id\": [\"T13\"], \"value\": \"Medium\"}}"
}
]
}
] |
6408978_1 | Intravenous diazepam exacerbated the seizures. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"exacerbated\"]], \"start\": [[21]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"seizures\"]], \"start\": [[37]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Intravenous diazepam\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Route\": {\"text\": [[\"Intravenous\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"diazepam\"]], \"start\": [[12]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
12494253_1 | After nine previous uncomplicated cycles she developed severe anaphylaxis to cisplatin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[45]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"she\"]], \"start\": [[41]], \"entity_id\": [\"T3\"], \"Gender\": {\"text\": [[\"she\"]], \"start\": [[41]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"severe anaphylaxis\"]], \"start\": [[55]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"cisplatin\"]], \"start\": [[77]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"cisplatin\"]], \"start\": [[77]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
7937287_1 | Cefuroxime-induced acute renal failure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[11]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Cefuroxime\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Cefuroxime\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"acute renal failure\"]], \"start\": [[19]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
11026106_3 | We describe the clinical and liver biopsy morphologic features for 4 patients with minocycline-induced autoimmune hepatitis (group 1). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[95]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"4 patients\"]], \"start\": [[67]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"4\"]], \"start\": [[67]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"minocycline\"]], \"start\": [[83]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"minocycline\"]], \"start\": [[83]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"autoimmune hepatitis\"]], \"start\": [[103]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
16371793_1 | Intravitreal triamcinolone acetonide for persisting cystoid macular edema after penetrating keratoplasty. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"for\"]], \"start\": [[37]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"ntravitreal triamcinolone acetonide\"]], \"start\": [[1]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"persisting cystoid macular edema\"]], \"start\": [[41]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"triamcinolone acetonide\"]], \"start\": [[13]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"Intravitreal\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[74]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"penetrating keratoplasty\"]], \"start\": [[80]], \"entity_id\": [\"T13\"]}, \"Effect\": {\"text\": [[\"persisting cystoid macular edema\"]], \"start\": [[41]], \"entity_id\": [\"T4\"]}, \"Severity\": {\"text\": [[\"persisting\"]], \"start\": [[41]], \"entity_id\": [\"T11\"], \"value\": \"High\"}}"
}
]
}
] |
24661191_4 | We report a case of a 29-year-old liver transplant patient who suffered liver injury most likely induced by drug interaction between capecitabine and warfarin. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[97]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"a 29-year-old liver transplant patient\"]], \"start\": [[20]], \"entity_id\": [\"T8\"], \"Age\": {\"text\": [[\"29-year-old\"]], \"start\": [[22]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"liver transplant\"]], \"start\": [[34]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"liver injury\"]], \"start\": [[72]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"drug interaction between capecitabine and warfarin\"]], \"start\": [[108]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"capecitabine\"], [\"warfarin\"]], \"start\": [[133], [150]], \"entity_id\": [\"T15\", \"T16\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[113]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"capecitabine\"], [\"warfarin\"]], \"start\": [[133], [150]], \"entity_id\": [\"T15\", \"T16\"]}}]}, \"Speculated\": {\"text\": [[\"most likely\"]], \"start\": [[85]], \"entity_id\": [\"T11\"], \"value\": true}}"
}
]
}
] |
11243427_3 | DISCUSSION: Patients with 5-FU-induced ectropion experience tender, red, scaled lids, making contact lens wear difficult. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[31]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"5-FU\"]], \"start\": [[26]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"5-FU\"]], \"start\": [[26]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"ectropion\"], [\"tender, red, scaled lids\"]], \"start\": [[39], [60]], \"entity_id\": [\"T7\", \"T9\"]}, \"Subject\": {\"text\": [[\"Patients with 5-FU-induced ectropion\"]], \"start\": [[12]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
15197722_3 | Restless legs syndrome may thus be an adverse effect of IFN alpha treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"adverse effect\"]], \"start\": [[38]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"IFN alpha treatment.\"]], \"start\": [[56]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"IFN alpha\"]], \"start\": [[56]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Restless legs syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[23]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
11093071_2 | Treatment of chronic hepatitis C with interferon alpha (IFN-alpha) is relatively contraindicated in patients with psychiatric disorders because of possible severe psychiatric side effects. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"contraindicated\"]], \"start\": [[81]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"interferon alpha (IFN-alpha)\"]], \"start\": [[38]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"chronic hepatitis C\"]], \"start\": [[13]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"interferon alpha\"]], \"start\": [[38]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"patients with psychiatric disorders\"]], \"start\": [[100]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"psychiatric disorders\"]], \"start\": [[114]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"possible severe psychiatric side effects\"]], \"start\": [[147]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
9494448_6 | METHODS: We report a patient who had an anaphylactic reaction during the intravenous infusion of cyclosporine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[62]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[19]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"anaphylactic reaction\"]], \"start\": [[40]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"intravenous infusion of cyclosporine\"]], \"start\": [[73]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"cyclosporine\"]], \"start\": [[97]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"intravenous infusion\"]], \"start\": [[73]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
18721173_2 | Gabapentin toxicity in renal failure: the importance of dose adjustment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"toxicity\"]], \"start\": [[11]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Gabapentin\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Gabapentin\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"renal failure\"]], \"start\": [[23]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
16854757_1 | We describe a case of a man treated with an EGFR-inhibitor (erlotinib) for a cell lung cancer who developed skin manifestations localized in an uncommon area and with an atypical evolution. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[98]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"a man\"]], \"start\": [[22]], \"entity_id\": [\"T4\"], \"Gender\": {\"text\": [[\"man\"]], \"start\": [[24]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"EGFR-inhibitor (erlotinib)\"]], \"start\": [[44]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"cell lung cancer\"]], \"start\": [[77]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"EGFR-inhibitor\"]], \"start\": [[44]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"skin manifestations localized in an uncommon area and with an atypical evolution\"]], \"start\": [[108]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
15671134_4 | We describe a case of clozapine-induced seizures in a patient with treatment-resistant schizophrenia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[32]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"clozapine\"]], \"start\": [[22]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"clozapine\"]], \"start\": [[22]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"treatment-resistant schizophrenia\"]], \"start\": [[67]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"seizures\"]], \"start\": [[40]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a patient with treatment-resistant schizophrenia\"]], \"start\": [[52]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
847572_3 | Two fatal cases of poisoning by paracetamol are described. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"by\"]], \"start\": [[29]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"paracetamol\"]], \"start\": [[32]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"paracetamol\"]], \"start\": [[32]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"Two fatal cases\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"Two\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"poisoning\"]], \"start\": [[19]], \"entity_id\": [\"T6\"]}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[4]], \"entity_id\": [\"T9\"], \"value\": \"High\"}}"
}
]
}
] |
3470173_4 | The neurotoxicity seen with HDARAC is dose-related and has occurred in up to 60 percent of treated patients. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[43]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"neurotoxicity\"]], \"start\": [[4]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"HDARAC\"]], \"start\": [[28]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"HDARAC\"]], \"start\": [[28]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"60 percent of treated patients\"]], \"start\": [[77]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"60 percent\"]], \"start\": [[77]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
11545487_5 | The HIV protease inhibitor indinavir may cause nephrolithiasis and interstitial nephritis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[41]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"HIV protease inhibitor indinavir\"]], \"start\": [[4]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"indinavir\"]], \"start\": [[27]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"nephrolithiasis and interstitial nephritis\"]], \"start\": [[47]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[37]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
9022114_1 | BACKGROUND: Colchicine has a known adverse effect on wound healing through its inhibitory effect on tubulin-dependent cell functions and through collagenase activation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"adverse effect\"]], \"start\": [[35]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Colchicine\"]], \"start\": [[12]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Colchicine\"]], \"start\": [[12]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"wound healing\"]], \"start\": [[53]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
1792646_1 | Pneumocystis carinii pneumonia as a complication of methotrexate treatment of asthma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[36]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Pneumocystis carinii pneumonia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"methotrexate\"]], \"start\": [[52]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[52]], \"entity_id\": [\"T6\"]}, \"Disorder\": {\"text\": [[\"asthma\"]], \"start\": [[78]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
14690166_5 | 2-CdA typically causes a long-lasting state of immunodeficiency and the profound influence of this drug on the immune system has raised questions concerning the emergence of secondary neoplasms after its use. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"causes\"]], \"start\": [[16]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"2-CdA\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"2-CdA\"]], \"start\": [[0]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"a long-lasting state of immunodeficiency\", \"emergence of secondary neoplasms after its use\"]], \"start\": [[23, 161]], \"entity_id\": [\"T11\"]}, \"Speculated\": {\"text\": [[\"questions\"]], \"start\": [[136]], \"entity_id\": [\"T13\"], \"value\": true}}"
}
]
}
] |
14700673_1 | CONCLUSIONS: Topiramate may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and anterior chamber shallowing, resulting in acute myopia and angle-closure glaucoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"resulting\"]], \"start\": [[157]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"Topiramate\"]], \"start\": [[13]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"Topiramate\"]], \"start\": [[13]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"acute myopia and angle-closure glaucoma\"]], \"start\": [[170]], \"entity_id\": [\"T13\"]}}"
}
]
}
] |
19745701_1 | Increased awareness is needed on the possible occurrence of LPD resembling gastric cancer in rheumatoid arthritis patients treated with MTX. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurrence\"]], \"start\": [[46]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"LPD\"]], \"start\": [[60]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"rheumatoid arthritis patients\"]], \"start\": [[93]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"MTX\"]], \"start\": [[136]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"rheumatoid arthritis\"]], \"start\": [[93]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"MTX\"]], \"start\": [[136]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
3195622_2 | A dapsone hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[187]], \"entity_id\": [\"T24\"]}, \"Treatment\": {\"text\": [[\"dapsone\"]], \"start\": [[2]], \"entity_id\": [\"T21\"], \"Drug\": {\"text\": [[\"dapsone\"]], \"start\": [[2]], \"entity_id\": [\"T25\"]}, \"Disorder\": {\"text\": [[\"leprosy\"]], \"start\": [[213]], \"entity_id\": [\"T26\"]}}, \"Effect\": {\"text\": [[\"hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis\"]], \"start\": [[10]], \"entity_id\": [\"T23\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[178]], \"entity_id\": [\"T22\"]}}"
}
]
}
] |
16371793_11 | CONCLUSIONS: Intravitreal injection of triamcinolone acetonide may be an additional tool in the treatment of therapy-resistant cystoid macular edema after penetrating keratoplasty. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[96]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Intravitreal injection of triamcinolone acetonide\"]], \"start\": [[13]], \"entity_id\": [\"T4\"], \"Route\": {\"text\": [[\"Intravitreal injection\"]], \"start\": [[13]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"triamcinolone acetonide\"]], \"start\": [[39]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"therapy-resistant cystoid macular edema\"]], \"start\": [[109]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
17458405_2 | Since its FDA approval in 2002, there are no known citations of ezetimibe-induced pancreatitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[74]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"ezetimibe\"]], \"start\": [[64]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"ezetimibe\"]], \"start\": [[64]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"pancreatitis\"]], \"start\": [[82]], \"entity_id\": [\"T5\"]}, \"Negated\": {\"text\": [[\"no\"]], \"start\": [[42]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
7272895_2 | Acute acoustic nerve palsy associated with vincristine therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[27]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"vincristine therapy\"]], \"start\": [[43]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"vincristine\"]], \"start\": [[43]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Acute acoustic nerve palsy\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
17852449_6 | Review of all reported cases of the use of ATRA in pregnancy revealed no serious adverse outcomes or congenital anomalies although only very few cases had exposure in the first trimester. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"revealed\"]], \"start\": [[61]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"ATRA\"]], \"start\": [[43]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"ATRA\"]], \"start\": [[43]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"in pregnancy\"]], \"start\": [[48]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"pregnancy\"]], \"start\": [[51]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"adverse outcomes or congenital anomalies\"]], \"start\": [[81]], \"entity_id\": [\"T10\"]}, \"Negated\": {\"text\": [[\"no\"]], \"start\": [[70]], \"entity_id\": [\"T14\"], \"value\": true}}"
}
]
}
] |
19857154_5 | The first patient was a 57-year-old man with HIV and bipolar disease who developed rapid and severe weight gain when quetiapine was added to a stable atazanavir-ritonavir-based antiretroviral regimen. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[73]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"a 57-year-old man with HIV and bipolar disease\"]], \"start\": [[22]], \"entity_id\": [\"T10\"], \"Age\": {\"text\": [[\"57-year-old\"]], \"start\": [[24]], \"entity_id\": [\"T14\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[36]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"rapid and severe weight gain\"]], \"start\": [[83]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"quetiapine was added to a stable atazanavir-ritonavir-based antiretroviral regimen\"]], \"start\": [[117]], \"entity_id\": [\"T13\"], \"Disorder\": {\"text\": [[\"HIV\"], [\"bipolar disease\"]], \"start\": [[45], [53]], \"entity_id\": [\"T1\", \"T2\"]}, \"Drug\": {\"text\": [[\"atazanavir\"], [\"ritonavir\"], [\"quetiapine\"]], \"start\": [[150], [161], [117]], \"entity_id\": [\"T4\", \"T5\", \"T6\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"added\"]], \"start\": [[132]], \"entity_id\": [\"T3\"]}, \"Drug\": {\"text\": [[\"quetiapine\"], [\"atazanavir\"], [\"ritonavir\"]], \"start\": [[117], [150], [161]], \"entity_id\": [\"T6\", \"T4\", \"T5\"]}}]}}"
}
]
}
] |
17009081_1 | A 43-year-old woman with multiple sclerosis (MS) had nephrotic syndrome 21 months after starting treatment with interferon (IFN)-beta-1b (subcutaneous administration). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"had\"]], \"start\": [[49]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"A 43-year-old woman with multiple sclerosis (MS)\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"43-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"nephrotic syndrome\"]], \"start\": [[53]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"21 months after starting treatment with interferon (IFN)-beta-1b (subcutaneous administration)\"]], \"start\": [[72]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"multiple sclerosis\"]], \"start\": [[25]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"interferon (IFN)-beta-1b\"]], \"start\": [[112]], \"entity_id\": [\"T10\"]}, \"Time_elapsed\": {\"text\": [[\"21 months\"]], \"start\": [[72]], \"entity_id\": [\"T1\"]}}}"
}
]
}
] |
17444802_4 | RESULTS: An 81-year-old man with a history of neoplasies of the colon and prostate and anticoagulant treatment was referred for treatment of an ocular surface neoplasia on his left eye. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"referred\"]], \"start\": [[115]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"anticoagulant\"]], \"start\": [[87]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"anticoagulant\"]], \"start\": [[87]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"neoplasies of the colon and prostate\"]], \"start\": [[46]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"an ocular surface neoplasia on his left eye\"]], \"start\": [[141]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"An 81-year-old man with a history of neoplasies of the colon and prostate\"]], \"start\": [[9]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"81-year-old\"]], \"start\": [[12]], \"entity_id\": [\"T11\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[24]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
16421117_1 | CONCLUSION: The present findings suggest that: (i) amantadine probably exerts its anti-dyskinetic effect by acting on the "indirect" pathway; (ii) the pathophysiological mechanisms of subthalamotomy induced dyskinesias may differ from those involved in L-dopa induced dyskinesias; (iii) dyskinesias induced by STN surgery resolve spontaneously as compensatory mechanisms develop. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"exerts\"]], \"start\": [[71]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"amantadine\"]], \"start\": [[51]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"amantadine\"]], \"start\": [[51]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"anti-dyskinetic effect\"]], \"start\": [[82]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"probably\"]], \"start\": [[62]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
15097937_3 | We report a case of a previously healthy, postmenopausal woman who developed anticonvulsant hypersensitivity syndrome while taking Bellamine S (belladonna alkaloids; ergotamine; phenobarbital) for hot flashes. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[67]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"a previously healthy, postmenopausal woman\"]], \"start\": [[20]], \"entity_id\": [\"T6\"], \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[57]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"anticonvulsant hypersensitivity syndrome\"]], \"start\": [[77]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Bellamine S (belladonna alkaloids; ergotamine; phenobarbital)\"]], \"start\": [[131]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"hot flashes\"]], \"start\": [[197]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"Bellamine S\"], [\"belladonna alkaloids\"], [\"ergotamine\"], [\"phenobarbital\"]], \"start\": [[131], [144], [166], [178]], \"entity_id\": [\"T13\", \"T14\", \"T15\", \"T16\"]}}}"
}
]
}
] |
2332596_3 | Skin rash began after 2 weeks of treatment, and signs of hepatocellular failure developed 3 weeks after phenobarbital had been started. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[80]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Skin rash\", \"hepatocellular failure\"]], \"start\": [[0, 57]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"phenobarbital\"]], \"start\": [[104]], \"entity_id\": [\"T7\"], \"Time_elapsed\": {\"text\": [[\"3 weeks\"], [\"2 weeks\"]], \"start\": [[90], [22]], \"entity_id\": [\"T8\", \"T9\"]}, \"Drug\": {\"text\": [[\"phenobarbital\"]], \"start\": [[104]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
10461415_1 | Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of ceftriaxone with elevated hepato-biliary enzymes and transient biliary stasis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"association of\"]], \"start\": [[111]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"elevated hepato-biliary enzymes and transient biliary stasis\"]], \"start\": [[143]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"ceftriaxone\"]], \"start\": [[126]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"otitis media\"]], \"start\": [[54]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"ceftriaxone\"]], \"start\": [[126]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
11487721_2 | A rare case of advanced ovarian carcinoma who developed difficulty walking 25 days after treatment with weekly paclitaxel. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[46]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"difficulty walking\"]], \"start\": [[56]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"25 days after treatment with weekly paclitaxel\"]], \"start\": [[75]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"advanced ovarian carcinoma\"]], \"start\": [[15]], \"entity_id\": [\"T3\"]}, \"Time_elapsed\": {\"text\": [[\"25 days\"]], \"start\": [[75]], \"entity_id\": [\"T7\"]}, \"Freq\": {\"text\": [[\"weekly\"]], \"start\": [[104]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"paclitaxel\"]], \"start\": [[111]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"A rare case of advanced ovarian carcinoma\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
7919557_5 | We report a case of cough following the administration of quinapril, with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[26]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"cough\"]], \"start\": [[20]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"the administration of quinapril\"]], \"start\": [[36]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"quinapril\"]], \"start\": [[58]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"hypertension\"]], \"start\": [[181]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"patient with essential hypertension\"]], \"start\": [[158]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
7321956_1 | Liver disease induced by perhexiline maleate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced by\"]], \"start\": [[14]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Liver disease\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"perhexiline maleate\"]], \"start\": [[25]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"perhexiline maleate\"]], \"start\": [[25]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
7606071_6 | OBJECTIVE: To report the occurrence of anaphylactoid reactions to intraperitoneal cisplatin in 3 patients. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"to\"]], \"start\": [[63]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"intraperitoneal cisplatin\"]], \"start\": [[66]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"cisplatin\"]], \"start\": [[82]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"intraperitoneal\"]], \"start\": [[66]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"3 patients.\"]], \"start\": [[95]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"3\"]], \"start\": [[95]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"anaphylactoid reactions\"]], \"start\": [[39]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
2329972_1 | In a female with acute lymphoblastic leukemia, inadvertent doxorubicin administration intrathecally caused severe, life-threatening, acute encephalopathy with high-pressure hydrocephalus. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[100]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"female with acute lymphoblastic leukemia\"]], \"start\": [[5]], \"entity_id\": [\"T5\"], \"Gender\": {\"text\": [[\"female\"]], \"start\": [[5]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"severe, life-threatening, acute encephalopathy with high-pressure hydrocephalus\"]], \"start\": [[107]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"inadvertent doxorubicin administration intrathecally\"]], \"start\": [[47]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"doxorubicin\"]], \"start\": [[59]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"acute lymphoblastic leukemia\"]], \"start\": [[17]], \"entity_id\": [\"T13\"]}, \"Route\": {\"text\": [[\"intrathecally\"]], \"start\": [[86]], \"entity_id\": [\"T14\"]}}, \"Severity\": {\"text\": [[\"severe, life-threatening, acute\"]], \"start\": [[107]], \"entity_id\": [\"T15\"], \"value\": \"High\"}}"
}
]
}
] |
12932249_2 | These skin lesions may be induced or worsened during antiviral therapy with interferon-alpha (IFN). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[26]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"skin lesions\"]], \"start\": [[6]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"antiviral therapy with interferon-alpha (IFN)\"]], \"start\": [[53]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"interferon-alpha (IFN).\"]], \"start\": [[76]], \"entity_id\": [\"T7\"]}}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[19]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
11144696_12 | Clinicians should be aware of the proepileptogenic effect of venlafaxine and trimipramine at therapeutic doses and that this combination may eventually increase the risk of seizures. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"eventually\"]], \"start\": [[141]], \"entity_id\": [\"T12\"]}, \"Effect\": {\"text\": [[\"increase the risk of seizures\"]], \"start\": [[152]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"venlafaxine and trimipramine at therapeutic doses\"]], \"start\": [[61]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"venlafaxine\"], [\"trimipramine\"]], \"start\": [[61], [77]], \"entity_id\": [\"T13\", \"T14\"]}, \"Dosage\": {\"text\": [[\"therapeutic doses\"]], \"start\": [[93]], \"entity_id\": [\"T17\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[73]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"venlafaxine\"], [\"trimipramine\"]], \"start\": [[61], [77]], \"entity_id\": [\"T13\", \"T14\"]}}]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[137]], \"entity_id\": [\"T18\"], \"value\": true}}"
}
]
}
] |
16298824_6 | We report the case of a 43-year-old man with ITP refractory to steroids and intravenous immunoglobulin who developed acute respiratory distress syndrome (ARDS) after a single infusion of rituximab. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[107]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"single infusion of rituximab\"]], \"start\": [[168]], \"entity_id\": [\"T5\"], \"Route\": {\"text\": [[\"infusion\"]], \"start\": [[175]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"rituximab\"]], \"start\": [[187]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"ITP\"]], \"start\": [[45]], \"entity_id\": [\"T1\"]}}, \"Effect\": {\"text\": [[\"acute respiratory distress syndrome (ARDS)\"]], \"start\": [[117]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"the case of a 43-year-old man with ITP refractory to steroids and intravenous immunoglobulin\"]], \"start\": [[10]], \"entity_id\": [\"T8\"], \"Age\": {\"text\": [[\"43-year-old\"]], \"start\": [[24]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[36]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"refractory to steroids and intravenous immunoglobulin\"]], \"start\": [[49]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
16573370_6 | She had been prescribed two mood stabilizers and suffered from anticholinergic adverse effects and the movement disorder tardive dyskinesia (TD). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"suffered from\"]], \"start\": [[49]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"prescribed two mood stabilizers\"]], \"start\": [[13]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"mood stabilizers\"]], \"start\": [[28]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"anticholinergic adverse effects and the movement disorder tardive dyskinesia (TD)\"]], \"start\": [[63]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
19357764_1 | CASE REPORT: We describe here a case of a 60 year old female that experienced a relapse of symptomatic hyperlactatemia after being switched from stavudine to zidovudine and how the case was managed at the Infectious Diseases Institute, Kampala, Uganda. | false | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[119]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a case of a 60 year old female\"]], \"start\": [[30]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"60 year old\"]], \"start\": [[42]], \"entity_id\": [\"T5\"]}, \"Gender\": {\"text\": [[\"female\"]], \"start\": [[54]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"relapse of symptomatic hyperlactatemia\"]], \"start\": [[80]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"switched from stavudine to zidovudine\"]], \"start\": [[131]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"stavudine\"], [\"zidovudine\"]], \"start\": [[145], [158]], \"entity_id\": [\"T10\", \"T11\"]}}}"
}
]
}
] |
2743258_1 | This report describes two patients who developed acute myelocytic leukemia only after exposure to cyclophosphamide, methotrexate, and 5-fluorouracil adjuvant therapy. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[39]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"two patients\"]], \"start\": [[22]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[22]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"acute myelocytic leukemia\"]], \"start\": [[49]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"exposure to cyclophosphamide, methotrexate, and 5-fluorouracil adjuvant therapy\"]], \"start\": [[86]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"cyclophosphamide\"], [\"methotrexate\"], [\"5-fluorouracil\"]], \"start\": [[98], [116], [134]], \"entity_id\": [\"T10\", \"T11\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[130]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"5-fluorouracil\"], [\"cyclophosphamide\"], [\"methotrexate\"]], \"start\": [[134], [98], [116]], \"entity_id\": [\"T12\", \"T10\", \"T11\"]}}]}}"
}
]
}
] |
1694575_1 | Reversible corneal keratinization following trabeculectomy and treatment with 5-fluorouracil. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[34]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Reversible corneal keratinization\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"5-fluorouracil\"]], \"start\": [[78]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"5-fluorouracil.\"]], \"start\": [[78]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
8742573_1 | CASE: We report a case of a woman with severe human insulin-induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[93]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"recombinant DNA human insulin\"]], \"start\": [[118]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"recombinant DNA human insulin\"]], \"start\": [[118]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"woman\"]], \"start\": [[28]], \"entity_id\": [\"T5\"], \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[28]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"severe human insulin-induced lipoatrophy\"]], \"start\": [[39]], \"entity_id\": [\"T6\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[39]], \"entity_id\": [\"T9\"], \"value\": \"High\"}}"
}
]
}
] |
16923659_6 | METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and carbamazepine) presenting with mixed SS/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presenting\"]], \"start\": [[123]], \"entity_id\": [\"T15\"]}, \"Treatment\": {\"text\": [[\"a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and carbamazepine)\"]], \"start\": [[25]], \"entity_id\": [\"T13\"], \"Drug\": {\"text\": [[\"venlafaxine\"], [\"topiramate\"], [\"divalproex sodium\"], [\"risperidone\"], [\"carbamazepine\"]], \"start\": [[47], [60], [72], [91], [108]], \"entity_id\": [\"T16\", \"T17\", \"T18\", \"T19\", \"T20\"]}, \"Dosage\": {\"text\": [[\"overdose\"]], \"start\": [[37]], \"entity_id\": [\"T21\"]}}, \"Effect\": {\"text\": [[\"mixed SS/NMS features\"]], \"start\": [[139]], \"entity_id\": [\"T14\"]}}"
}
]
}
] |
17526968_2 | Hyperpigmentation is one of the cutaneous side effects of chemotherapautic agents, but it is usually accepted as a cosmetic problem. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"of\"]], \"start\": [[55]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Hyperpigmentation\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"chemotherapautic agents\"]], \"start\": [[58]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"chemotherapautic agents\"]], \"start\": [[58]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
17352036_2 | Pancreatitis is a very rare adverse effect associated with the use of amiodarone, and only four cases of amiodarone-induced pancreatitis have been reported in literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[116]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"pancreatitis\"]], \"start\": [[124]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"amiodarone\"]], \"start\": [[105]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"amiodarone\"]], \"start\": [[105]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"four cases\"]], \"start\": [[91]], \"entity_id\": [\"T8\"], \"Population\": {\"text\": [[\"four\"]], \"start\": [[91]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
3773837_1 | The latter form (Macrodantin) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--liver damage, acute and chronic pulmonary reactions, peripheral neuropathy, blood dyscrasias and allergic reactions--and does so just as rapidly and floridly; one such case is reported here. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"adverse effects\"]], \"start\": [[116]], \"entity_id\": [\"T13\"]}, \"Treatment\": {\"text\": [[\"Macrodantin\"]], \"start\": [[17]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"Macrodantin\"]], \"start\": [[17]], \"entity_id\": [\"T18\"]}}, \"Effect\": {\"text\": [[\"less gastrointestinal intolerance\", \"liver damage, acute and chronic pulmonary reactions, peripheral neuropathy, blood dyscrasias and allergic reactions\"]], \"start\": [[54, 158]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"one such case\"]], \"start\": [[317]], \"entity_id\": [\"T14\"], \"Population\": {\"text\": [[\"one\"]], \"start\": [[317]], \"entity_id\": [\"T15\"]}}, \"Speculated\": {\"text\": [[\"can\"]], \"start\": [[95]], \"entity_id\": [\"T17\"], \"value\": true}}"
}
]
}
] |
18176653_4 | CASE REPORT: A 29-year-old black man, HIV-infected since 1996, began highly active antiretroviral therapy (HAART) with zidovudine, lamivudine, and indinavir. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"began\"]], \"start\": [[63]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"A 29-year-old black man, HIV-infected since 1996\"]], \"start\": [[13]], \"entity_id\": [\"T10\"], \"Age\": {\"text\": [[\"29-year-old\"]], \"start\": [[15]], \"entity_id\": [\"T13\"]}, \"Race\": {\"text\": [[\"black\"]], \"start\": [[27]], \"entity_id\": [\"T14\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[33]], \"entity_id\": [\"T15\"]}}, \"Treatment\": {\"text\": [[\"highly active antiretroviral therapy (HAART) with zidovudine, lamivudine, and indinavir\"]], \"start\": [[69]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"zidovudine\"], [\"lamivudine\"], [\"indinavir\"]], \"start\": [[119], [131], [147]], \"entity_id\": [\"T17\", \"T18\", \"T19\"]}, \"Disorder\": {\"text\": [[\"HIV\"]], \"start\": [[38]], \"entity_id\": [\"T1\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[143]], \"entity_id\": [\"T20\"]}, \"Drug\": {\"text\": [[\"zidovudine\"], [\"lamivudine\"], [\"indinavir\"]], \"start\": [[119], [131], [147]], \"entity_id\": [\"T17\", \"T18\", \"T19\"]}}]}}"
}
]
}
] |
20118434_3 | METHOD: The authors followed a patient with chronic HCV who received interferon and ribavirin and who developed hallucinations ultimately requiring psychiatric hospitalization. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[102]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"a patient with chronic HCV\"]], \"start\": [[29]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"interferon and ribavirin\"]], \"start\": [[69]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"interferon\"], [\"ribavirin\"]], \"start\": [[69], [84]], \"entity_id\": [\"T9\", \"T11\"]}, \"Disorder\": {\"text\": [[\"chronic HCV\"]], \"start\": [[44]], \"entity_id\": [\"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[80]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"interferon\"], [\"ribavirin\"]], \"start\": [[69], [84]], \"entity_id\": [\"T9\", \"T11\"]}}]}, \"Effect\": {\"text\": [[\"hallucinations\"]], \"start\": [[112]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
19733945_3 | This case of linezolid-associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[23]], \"entity_id\": [\"T13\"]}, \"Effect\": {\"text\": [[\"acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms (DRESS) syndrome\"]], \"start\": [[34]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"linezolid\"]], \"start\": [[13]], \"entity_id\": [\"T1\"], \"Drug\": {\"text\": [[\"linezolid\"]], \"start\": [[13]], \"entity_id\": [\"T15\"]}}}"
}
]
}
] |
15359206_1 | Easily reversible hypoxemia and hypotension induced by nimodipine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[44]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"hypoxemia and hypotension\"]], \"start\": [[18]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"nimodipine\"]], \"start\": [[55]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"nimodipine\"]], \"start\": [[55]], \"entity_id\": [\"T8\"]}}, \"Severity\": {\"text\": [[\"Easily reversible\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"value\": \"Low\"}}"
}
]
}
] |
17352036_1 | Adverse effects of amiodarone including pulmonary toxicity, hepatotoxicity, aggravation of arrhythmia, and thyroid diseases are well understood. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"including\"]], \"start\": [[30]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"amiodarone\"]], \"start\": [[19]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"amiodarone\"]], \"start\": [[19]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"pulmonary toxicity, hepatotoxicity, aggravation of arrhythmia, and thyroid diseases\"]], \"start\": [[40]], \"entity_id\": [\"T11\"]}}"
}
]
}
] |
3977377_1 | Chronic photosensitivity associated with hydrochlorothiazide ingestion occurred in four patients. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[25]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Chronic photosensitivity\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"four patients\"]], \"start\": [[83]], \"entity_id\": [\"T4\"], \"Population\": {\"text\": [[\"four\"]], \"start\": [[83]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"hydrochlorothiazide ingestion\"]], \"start\": [[41]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"hydrochlorothiazide\"]], \"start\": [[41]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"ingestion\"]], \"start\": [[61]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
4054170_2 | Chlorambucil central nervous toxicity: a significant side effect of chlorambucil therapy in childhood nephrotic syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"side effect\"]], \"start\": [[53]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Chlorambucil\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Chlorambucil\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"childhood nephrotic syndrome\"]], \"start\": [[92]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"central nervous toxicity\"]], \"start\": [[13]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
25671244_3 | The mechanism of action of this centrally acting muscle relaxant is unknown; however, the observation of serotonin syndrome in patients with metaxalone overdose suggests a role in the serotonergic pathway. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[124]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"centrally acting muscle relaxant\", \"metaxalone overdose\"]], \"start\": [[32, 141]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"centrally acting muscle relaxant\"], [\"metaxalone\"]], \"start\": [[32], [141]], \"entity_id\": [\"T9\", \"T10\"]}, \"Dosage\": {\"text\": [[\"overdose\"]], \"start\": [[152]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"serotonin syndrome\"]], \"start\": [[105]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[127]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
12598508_2 | In general, angiotensin converting enzyme (ACE) inhibitors should be discontinued in pregnancy, as they can induce an ACE fetopathy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induce\"]], \"start\": [[108]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"ACE fetopathy\"]], \"start\": [[118]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"angiotensin converting enzyme (ACE) inhibitors\"]], \"start\": [[12]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"angiotensin converting enzyme (ACE) inhibitors\"]], \"start\": [[12]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"pregnancy\"]], \"start\": [[85]], \"entity_id\": [\"T12\"], \"Disorder\": {\"text\": [[\"pregnancy\"]], \"start\": [[85]], \"entity_id\": [\"T8\"]}}, \"Speculated\": {\"text\": [[\"can\"]], \"start\": [[104]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
1993143_1 | Of 371 patients treated with 8MOP, three (0.8%) developed an acute dermatitis in the PUVA-treated areas. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[48]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"acute dermatitis\"]], \"start\": [[61]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"Of 371 patients\", \"three (0.8%)\"]], \"start\": [[0, 35]], \"entity_id\": [\"T4\"], \"Population\": {\"text\": [[\"371\", \"three (0.8%)\"]], \"start\": [[3, 35]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"treated with 8MOP\"]], \"start\": [[16]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"8MOP\"]], \"start\": [[29]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
1174301_1 | There is a putative role of liothyronine administration in precipitating or activating hyperthyroidism. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"precipitating or activating\"]], \"start\": [[59]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"hyperthyroidism\"]], \"start\": [[87]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"liothyronine\"]], \"start\": [[28]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"liothyronine\"]], \"start\": [[28]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
16436462_1 | Neutropenic colitis during standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Neutropenic colitis\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer\"]], \"start\": [[27]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"testicular cancer\"]], \"start\": [[101]], \"entity_id\": [\"T6\"]}, \"Dosage\": {\"text\": [[\"standard dose\"]], \"start\": [[27]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"nedaplatin\"], [\"irinotecan\"]], \"start\": [[71], [86]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combination\"]], \"start\": [[41]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"nedaplatin\"], [\"irinotecan\"]], \"start\": [[71], [86]], \"entity_id\": [\"T10\", \"T11\"]}}]}}"
}
]
}
] |
17383767_2 | Brain metastases are a frequent finding in patients with advanced non-small cell lung cancer and concomitant administration of antiepileptic and chemotherapeutic drugs or epidermal growth factor receptor (EGFR) inhibitor is necessary in many cases. | true | [
{
"events": [
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"necessary\"]], \"start\": [[224]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"concomitant administration of antiepileptic and chemotherapeutic drugs or epidermal growth factor receptor (EGFR) inhibitor\"]], \"start\": [[97]], \"entity_id\": [\"T15\"], \"Drug\": {\"text\": [[\"antiepileptic\"], [\"chemotherapeutic\"], [\"epidermal growth factor receptor (EGFR) inhibitor\"]], \"start\": [[127], [145], [171]], \"entity_id\": [\"T11\", \"T12\", \"T13\"]}, \"Disorder\": {\"text\": [[\"Brain metastases\"]], \"start\": [[0]], \"entity_id\": [\"T18\"]}, \"Combination\": [{\"event_id\": \"E1\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[141]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"antiepileptic\"], [\"chemotherapeutic\"]], \"start\": [[127], [145]], \"entity_id\": [\"T11\", \"T12\"]}}]}, \"Subject\": {\"text\": [[\"patients with advanced non-small cell lung cancer\"]], \"start\": [[43]], \"entity_id\": [\"T16\"], \"Disorder\": {\"text\": [[\"advanced non-small cell lung cancer\"]], \"start\": [[57]], \"entity_id\": [\"T17\"]}}}"
}
]
}
] |
18343993_2 | A female patient with HER2 positive, metastatic breast cancer presented with pulmonary infiltrates, and a plural effusion dyspnoea after several months of trastuzumab treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presented\"]], \"start\": [[62]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"A female patient with HER2 positive, metastatic breast cancer\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Gender\": {\"text\": [[\"female\"]], \"start\": [[2]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"trastuzumab\"]], \"start\": [[155]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"HER2 positive, metastatic breast cancer\"]], \"start\": [[22]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"trastuzumab\"]], \"start\": [[155]], \"entity_id\": [\"T11\"]}, \"Time_elapsed\": {\"text\": [[\"several months\"]], \"start\": [[137]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"pulmonary infiltrates, and a plural effusion dyspnoea\"]], \"start\": [[77]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
12944250_3 | Thrombocytosis under ciprofloxacin and tazobactam/piperacillin. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"under\"]], \"start\": [[15]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Thrombocytosis\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"ciprofloxacin and tazobactam/piperacillin\"]], \"start\": [[21]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"ciprofloxacin\"], [\"tazobactam\"], [\"piperacillin\"]], \"start\": [[21], [39], [50]], \"entity_id\": [\"T11\", \"T12\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[35]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"ciprofloxacin\"], [\"tazobactam\"], [\"piperacillin\"]], \"start\": [[21], [39], [50]], \"entity_id\": [\"T11\", \"T12\", \"T13\"]}}]}}"
}
]
}
] |
7781845_2 | Quinine and its isomer quinidine are well-known causes of iatrogenic hypoglycaemia, due to excessive insulin secretion. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"causes\"]], \"start\": [[48]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Quinine and its isomer quinidine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"Quinine\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"iatrogenic hypoglycaemia, due to excessive insulin secretion\"]], \"start\": [[58]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
14690166_6 | Therefore, it is reasonable to conclude that: 1) 2-CdA can induce durable complete remission in MCD patients but unfortunately it cannot cure the disease; 2) the possibility that 2-CdA may accelerate the transformation of MCD to NHL cannot be ruled out. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"induce\"]], \"start\": [[59]], \"entity_id\": [\"T18\"]}, \"Effect\": {\"text\": [[\"durable complete remission\"]], \"start\": [[66]], \"entity_id\": [\"T19\"]}, \"Treatment\": {\"text\": [[\"2-CdA\"]], \"start\": [[49]], \"entity_id\": [\"T15\"], \"Disorder\": {\"text\": [[\"MCD\"]], \"start\": [[96]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"2-CdA\"]], \"start\": [[49]], \"entity_id\": [\"T16\"]}}, \"Speculated\": {\"text\": [[\"can\"]], \"start\": [[55]], \"entity_id\": [\"T17\"], \"value\": true}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"accelerate\"]], \"start\": [[189]], \"entity_id\": [\"T20\"]}, \"Treatment\": {\"text\": [[\"2-CdA\"]], \"start\": [[179]], \"entity_id\": [\"T22\"], \"Drug\": {\"text\": [[\"2-CdA\"]], \"start\": [[179]], \"entity_id\": [\"T23\"]}}, \"Effect\": {\"text\": [[\"the transformation of MCD to NHL\"]], \"start\": [[200]], \"entity_id\": [\"T24\"]}, \"Speculated\": {\"text\": [[\"possibility\"]], \"start\": [[162]], \"entity_id\": [\"T21\"], \"value\": true}}"
}
]
}
] |
8192712_3 | Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[47]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Hyperammonemia\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"valproic acid\"]], \"start\": [[28]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"valproic acid\"]], \"start\": [[28]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"a postictal patient\"]], \"start\": [[68]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
11215836_2 | OBJECTIVE: To report on the possible development of serotonin syndrome in a patient receiving clomipramine after clozapine was withdrawn from the treatment regimen. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[84]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"clomipramine\"]], \"start\": [[94]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"clomipramine\"], [\"clozapine\"]], \"start\": [[94], [113]], \"entity_id\": [\"T8\", \"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[107]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"clomipramine\"], [\"clozapine\"]], \"start\": [[94], [113]], \"entity_id\": [\"T8\", \"T9\"]}}]}, \"Effect\": {\"text\": [[\"serotonin syndrome\"]], \"start\": [[52]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[76]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"possible\"]], \"start\": [[28]], \"entity_id\": [\"T11\"], \"value\": true}}"
}
]
}
] |
7295427_1 | Fatal ventricular fibrillation after treatment with digoxin in a 27-year-old man with mitral leaflet prolapse syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[31]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"digoxin\"]], \"start\": [[52]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"digoxin\"]], \"start\": [[52]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"mitral leaflet prolapse syndrome\"]], \"start\": [[86]], \"entity_id\": [\"T12\"]}}, \"Subject\": {\"text\": [[\"a 27-year-old man with mitral leaflet prolapse syndrome\"]], \"start\": [[63]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"27-year-old\"]], \"start\": [[65]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[77]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"Fatal ventricular fibrillation\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Severity\": {\"text\": [[\"Fatal\"]], \"start\": [[0]], \"entity_id\": [\"T10\"], \"value\": \"Medium\"}}"
}
]
}
] |
8641617_4 | Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[30]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Clostridium difficile colitis\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"cisplatin-based chemotherapy\"]], \"start\": [[46]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"cisplatin\"]], \"start\": [[46]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"ovarian cancer\"]], \"start\": [[78]], \"entity_id\": [\"T9\"]}, \"Route\": {\"text\": [[\"chemotherapy\"]], \"start\": [[62]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"ovarian cancer patients.\"]], \"start\": [[78]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
8828999_2 | Lithium-induced Creutzfeldt-Jakob syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[8]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Lithium\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Lithium\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Creutzfeldt-Jakob syndrome\"]], \"start\": [[16]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
12944250_1 | It is concluded that simultaneous administration of ciprofloxacin and tazobactam/piperacillin may cause marked thrombocytosis. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[98]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"simultaneous administration of ciprofloxacin and tazobactam/piperacillin\"]], \"start\": [[21]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"ciprofloxacin\"], [\"tazobactam/piperacillin\"]], \"start\": [[52], [70]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[66]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"ciprofloxacin\"], [\"tazobactam/piperacillin\"]], \"start\": [[52], [70]], \"entity_id\": [\"T9\", \"T10\"]}}]}, \"Effect\": {\"text\": [[\"marked thrombocytosis\"]], \"start\": [[104]], \"entity_id\": [\"T8\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[94]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
12121061_6 | Alone or in combination with corticosteroids, cyclosporine is an effective drug of choice for the resistant patients. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"is\"]], \"start\": [[59]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Alone or in combination with corticosteroids, cyclosporine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"corticosteroids\"], [\"cyclosporine\"]], \"start\": [[29], [46]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combination\"]], \"start\": [[12]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"corticosteroids\"], [\"cyclosporine\"]], \"start\": [[29], [46]], \"entity_id\": [\"T10\", \"T11\"]}}]}, \"Subject\": {\"text\": [[\"resistant patients\"]], \"start\": [[98]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
15013892_1 | Bull's-eye maculopathy associated with quinacrine therapy for malaria. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[23]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Bull's-eye maculopathy\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"quinacrine\"]], \"start\": [[39]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"quinacrine\"]], \"start\": [[39]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"malaria\"]], \"start\": [[62]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
11545487_4 | Physicians should be aware that indinavir nephrolithiasis may cause papillary necrosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[62]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"indinavir nephrolithiasis\"]], \"start\": [[32]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"indinavir\"]], \"start\": [[32]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"papillary necrosis\"]], \"start\": [[68]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[58]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
2394154_2 | Following the institution of intravenous therapy with acyclovir, the patient developed fever, hemoptysis, and a pleural friction rub. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[77]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"acyclovir\"]], \"start\": [[54]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"acyclovir\"]], \"start\": [[54]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"the patient\"]], \"start\": [[65]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"fever, hemoptysis, and a pleural friction rub\"]], \"start\": [[87]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
16637972_3 | Due to discomfort, diplopia and lagophthalmos, the haematoma necessitated suspension of warfarin therapy and a surgical evacuation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"Due to\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}, \"Effect\": {\"text\": [[\"discomfort, diplopia and lagophthalmos, the haematoma\"]], \"start\": [[7]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"warfarin therapy and a surgical evacuation\"]], \"start\": [[88]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"warfarin\"]], \"start\": [[88]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
9476721_1 | Acute dystonia with thalamic and brainstem lesions after initial penicillamine treatment in Wilson's disease. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[51]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Acute dystonia with thalamic and brainstem lesions\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"penicillamine\"]], \"start\": [[65]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"penicillamine\"]], \"start\": [[65]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"Wilson's disease\"]], \"start\": [[92]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
12862258_2 | Fatal agranulocytosis in an Indian male receiving 100mg of dapsone daily, hospitalized for mid-borderline leprosy in type I reaction with triple nerve paralysis is reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[40]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"mid-borderline leprosy in type I reaction with triple nerve paralysis\"]], \"start\": [[91]], \"entity_id\": [\"T3\"], \"Race\": {\"text\": [[\"Indian\"]], \"start\": [[28]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"male\"]], \"start\": [[35]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"Fatal agranulocytosis\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"100mg of dapsone daily\"]], \"start\": [[50]], \"entity_id\": [\"T5\"], \"Dosage\": {\"text\": [[\"100mg\"]], \"start\": [[50]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"dapsone\"]], \"start\": [[59]], \"entity_id\": [\"T11\"]}, \"Freq\": {\"text\": [[\"daily\"]], \"start\": [[67]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"mid-borderline leprosy in type I reaction with triple nerve paralysis\"]], \"start\": [[91]], \"entity_id\": [\"T13\"]}}, \"Severity\": {\"text\": [[\"Fatal\"]], \"start\": [[0]], \"entity_id\": [\"T14\"], \"value\": \"High\"}}"
}
]
}
] |
17285101_2 | The authors presented a case of pulmonary hypertension during lithium therapy, while she has been on lithium for 6 years. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[55]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"pulmonary hypertension\"]], \"start\": [[32]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"lithium therapy\"]], \"start\": [[62]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"lithium\"]], \"start\": [[62]], \"entity_id\": [\"T9\"]}, \"Duration\": {\"text\": [[\"6 years\"]], \"start\": [[113]], \"entity_id\": [\"T1\"]}}, \"Subject\": {\"text\": [[\"she\"]], \"start\": [[85]], \"entity_id\": [\"T6\"], \"Gender\": {\"text\": [[\"she\"]], \"start\": [[85]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
16968538_2 | BACKGROUND: Oxaliplatin is a platinum derivative, which is used in the treatment of colorectal cancer. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[71]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Oxaliplatin is a platinum derivative\"]], \"start\": [[12]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Oxaliplatin\"], [\"platinum derivative\"]], \"start\": [[12], [29]], \"entity_id\": [\"T8\", \"T9\"]}, \"Disorder\": {\"text\": [[\"colorectal cancer\"]], \"start\": [[84]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
17406804_2 | After having received gemcitabine on day 1 of the second course, the patient developed dry cough, subfebrile temperatures and dyspnea within 48 h. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[77]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"received gemcitabine on day 1 of the second course\"]], \"start\": [[13]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"gemcitabine\"]], \"start\": [[22]], \"entity_id\": [\"T11\"]}, \"Time_elapsed\": {\"text\": [[\"within 48 h\"]], \"start\": [[134]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"the patient\"]], \"start\": [[65]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"dry cough, subfebrile temperatures and dyspnea within 48 h\"]], \"start\": [[87]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
15454180_2 | As linezolid has been shown to have hematologic side effects, blood count monitoring is recommended in patients receiving this drug for long-term therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"have\"]], \"start\": [[31]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"linezolid\"]], \"start\": [[3]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"linezolid\"]], \"start\": [[3]], \"entity_id\": [\"T6\"]}, \"Duration\": {\"text\": [[\"long-term\"]], \"start\": [[136]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"hematologic side effects\"]], \"start\": [[36]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
189279_3 | The role of Adriamycin in the production of cardiotoxicity is reviewed. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"production\"]], \"start\": [[30]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Adriamycin\"]], \"start\": [[12]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Adriamycin\"]], \"start\": [[12]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"cardiotoxicity\"]], \"start\": [[44]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
7663030_5 | He began taking propafenone only 6 days prior to admission because of uncontrolled atrial fibrillation and symptoms of fatigue. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"taking\"]], \"start\": [[9]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"propafenone\"]], \"start\": [[16]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"propafenone\"]], \"start\": [[16]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"atrial fibrillation\"], [\"fatigue\"]], \"start\": [[83], [119]], \"entity_id\": [\"T8\", \"T10\"]}}}"
}
]
}
] |
12013364_1 | A 53-year-old man developed NMS without rigidity while taking olanzapine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[18]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"A 53-year-old man\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"53-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"NMS without rigidity\"]], \"start\": [[28]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"olanzapine\"]], \"start\": [[62]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"olanzapine\"]], \"start\": [[62]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
10650865_2 | We report on a 14-year-old boy with severe haemophilia A who developed a portal vein thrombosis during continuous infusion of F VIII. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[61]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a 14-year-old boy with severe haemophilia A\"]], \"start\": [[13]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"14-year-old\"]], \"start\": [[15]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"boy\"]], \"start\": [[27]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"a portal vein thrombosis\"]], \"start\": [[71]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"continuous infusion of F VIII\"]], \"start\": [[103]], \"entity_id\": [\"T6\"], \"Freq\": {\"text\": [[\"continuous\"]], \"start\": [[103]], \"entity_id\": [\"T10\"]}, \"Route\": {\"text\": [[\"infusion\"]], \"start\": [[114]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"F VIII\"]], \"start\": [[126]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"haemophilia A\"]], \"start\": [[43]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.